Our facilities

Our modern facilities and a commitment to investment in new premises ensure we continue to deliver leading edge translational research.

Dedicated research treatment facilities

The Oak Foundation Drug Development Unit (first-in-person studies) and West Wing Clinical Research Centre (phase Ib, II and complex phase III studies) enhance our recruitment to early clinical trials, patient experience of research and tissue acquisition infrastructure.

Imaging and imaged-guided therapies

The NIHR Imaging CRF provides essential capacity for BRC clinical trials, particularly in novel therapeutics that require incorporation of imaging protocols. 

The MR Linac facility houses one of the world’s most advanced radiotherapy machines combining a state-of-the-art radiation machine with a magnetic resonance imaging scanner.

Molecular diagnostics and biobanking

The Centre for Molecular Pathology is a purpose-built centre in Sutton, which was opened in 2012 by Professor Dame Sally Davies, Chief Medical Officer of England. It provides an innovative environment with state-of-the art laboratories, co-locating BRC researchers (clinicians, pathologists, geneticists and other scientists), a Molecular Diagnostics Laboratory and a dedicated bio-banking facility.

The Tumour Profiling Unit supports our vision for patients to have their tumour profiled at diagnosis and throughout treatment so their management plan can be adjusted every time a molecular change occurs. Using the latest next-generation genetic sequencing technologies the Unit classifies tumours by their genetics and find ways of personalising treatment to the particular mutations driving them.

The Ralph Lauren Centre for Breast Cancer Research is a Chelsea-based facility consolidating all clinical research development and staff in one area alongside clinical space, helping to ensure maximum benefits to our patients. The Centre aims to identify molecular differences between tumours that allow the optimal treatment of individual breast cancer patients.

Dedicated clinical trials units

The Royal Marsden Clinical Trials Unit became a fully registered UK Clinical Research Collaboration (UKCRC) Clinical Trials Unit in 2018 and manages novel early phase single or multi-centre interventional trials, acting as a facilitator and coordinator for designing, carrying out and analysing high quality and robust clinical trials.

The ICR Clinical Trials and Statistics Unit leads the design, conduct and analysis of phase II and III national and international cancer clinical trials. The Unit specialises in phase II exploratory and phase III randomised trials of new treatments and technologies.